HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Elizabeth R. Plimack, MD, MS, FASCO
Shilpa Gupta, MD
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Lillibeth Velasco, MSN, RN
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Diagnosis and Management of Metastatic PDAC
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Chemotherapy Strategies for Metastatic PDAC
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Sara Lonardi, MD
Aparna R. Parikh, MD
Alan Venook, MD
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.